PCa Commentary #152: Genomic Sequencing and Genomic Classifiers: Aids to Decision Making. A primer just to provide a ‘heads-up’.

by Dr. Ed Weber | Apr 13, 2021 | PCa Commentary

Genomic classifier panels for risk stratification and whole-genome sequencing in search of actionable mutations both provide personal molecular data that can guide management decisions. However, each provides an entirely different category of information. Both are...

PCa Commentary #151: OLIGOMETASTATIC PROSTATE CANCER: Metastases Directed Therapy – Patient Selection, Imaging and Outcomes

by Dr. Ed Weber | Mar 25, 2021 | PCa Commentary

Metastases Directed Therapy (MDT) has become a realistic option for men who develop metastases after primary therapy. The theoretical foundation of MDT was succinctly stated by David Palma, M.D., PhD:             “The oligometastatic paradigm hypothesizes that...

PCa Commentary #150 – Bone Health: An Important Issue Insufficiently Acknowledged for Men on Androgen Suppression

by Dr. Ed Weber | Feb 25, 2021 | PCa Commentary

A Commentary discussing bone health and bone protective therapy may not be as eye-catching as new developments in PSMA and Axumin imaging or radioligand therapy with Lu-177, but as the old spiritual says:    “dem bones, dem bones gonna walk around …”  and we...

PCa Commentary #149 – LUPRON vs FIRMAGON: Is The Debate About Superiority Over? Just the Facts, Please, … but with the December FDA approval of Relugolix the debate may now be moot.

by Dr. Ed Weber | Feb 3, 2021 | PCa Commentary

A great deal has been written about the comparison between Lupron (leuprolide) and Firmagon (degarelix). Lupron as been the mainstay of treatment of relapsed and metastatic prostate cancer since its introduction in the early 1990’s.  Firmagon (degarelix) was FDA...

PCaCommentary #148: ACTIVE SURVEILLANCE – What’s New.

by Dr. Ed Weber | Jan 19, 2021 | PCa Commentary

Active surveillance (AS) is an increasingly recommended strategy for carefully selected men with a biopsy diagnosis of low grade, localized prostate cancer.  It involves delaying primary intervention with careful follow-up monitoring with a goal of avoiding...

PCa Commentary #147: Olaparib and Rucaparib (PARP inhibitors)

by Dr. Ed Weber | Nov 17, 2020 | PCa Commentary

OLAPARIB and RUCAPARIB (PARP inhibitors): These newly FDA approved agents now offer a much needed additional treatment option for men with metastatic castration resistant prostate cancer (mCRPC). The prostate cancer field is abuzz with encouraging reports of efficacy...